GRI Bio GRI 深沪

等待开盘 02-03 09:30:00 美东时间

2.86

-0.400

-12.27%

华盛通

立即下载

最高3.236
今开3.22
成交量 25.36万股
最低 2.71
昨收 3.26
总市值 153.38万
52周最高 311.36
市盈率 ^静 --
换手率 47.29%
52周最低 2.71
委比 66.67%
总股本 53.63万
历史最高 64792072.80
量比 0.09
振幅 16.13%
历史最低 2.71
每手 1
风险率 66.36%

个股概要

财务分析

公司资料

分红派息

分时图
日k
周k
月k

相关新闻

BRIEF-GRI Bio May Offer Up To $250 Million In Securities - SEC Filing

BRIEF-GRI Bio May Offer Up To $250 Million In Securities - SEC Filing Jan 30 (Reuters) - GRI Bio Inc GRI.O : GRI BIO INC - MAY OFFER UP TO $250 MILLION IN SECURITIES - SEC FILING Source text: [ID:n0001824293-26-000028] Further company coverage: GRI.O (( Reuters.Briefs@thomsonreuters.com ;))

01-30 19:09
12 Health Care Stocks Moving In Thursday's Pre-Market Session

Gainers Greenwich LifeSciences (NASDAQ:GLSI) shares rose 48.6% to $33.13 durin...

01-22 20:05
GRI Bio shares are trading lower after the company announced it approved a 1-for-28 reverse stock split.

GRI Bio shares are trading lower after the company announced it approved a 1-fo...

01-22 05:18
GRI Bio Shareholders Authorize Reverse Stock Split Plan

GRI Bio ( ($GRI) ) just unveiled an announcement. On January 15, 2026, GRI Bio,...

01-15 23:47
GRI Bio Expands At-The-Market Equity Offering Capacity

The latest announcement is out from GRI Bio ( ($GRI) ). On January 9, 2026, GRI...

01-09 21:59
12 Health Care Stocks Moving In Thursday's After-Market Session

Gainers Shuttle Pharmaceuticals (NASDAQ:SHPH) shares moved upwards by 14.1% to...

01-09 05:06
GRI Bio Announced Cytometry Data From Phase 2a GRI-0621-IPF-02 Clinical Trial Evaluating GRI-0621 For Treatment Of Idiopathic Pulmonary Fibrosis

New immune profiling data confirms disease-modifying mechanism, reinforces earlier signals of fibrosis resolution, lung repair, and improved lung functionLA JOLLA, CA, Jan. 08, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc.

01-08 21:03
GRI Bio Announces Additional Positive Data from Phase 2a Study in Idiopathic Pulmonary Fibrosis, Strengthening Clinical Proof-of-Concept for GRI-0621

GRI Bio, Inc. announced positive data from its Phase 2a clinical trial for GRI-0621, showing immune cell modulation in Idiopathic Pulmonary Fibrosis (IPF) patients. The study revealed inhibition of iNKT cells, increased anti-fibrotic cytokines (IFN-γ), and reduced pro-fibrotic cytokines (IL-4, IL-13, IL-17A, IL-22, TGF-β). T cell receptor expression also increased after 12 weeks of treatment. The results reinforce GRI-0621's potential as a diseas...

01-08 13:00
Why Fonar Shares Are Trading Higher By Over 24%; Here Are 20 Stocks Moving Premarket

Shares of Fonar Corp (NASDAQ:FONR) rose sharply in pre-market after the company...

2025-12-30 17:43
GRI Bio Launches $6.7 Million Public Offering

GRI Bio ( ($GRI) ) has shared an update. On December 11, 2025, GRI Bio, Inc. in...

2025-12-12 22:00

派息除权日	每股总股息	派息日期
2023-03-23	0.63	2023-03-28
2022-12-22	0.53	2022-12-29
2022-09-22	0.45	2022-09-29
2022-06-23	0.48	2022-06-30
2022-03-24	0.52	2022-03-31
2021-12-22	0.56	2021-12-29
2021-09-23	0.44	2021-09-30
2021-06-17	0.47	2021-06-24
2021-03-18	0.51	2021-03-25
2020-12-22	0.64	2020-12-30
2020-09-17	0.35	2020-09-24
2020-06-18	0.42	2020-06-25
2020-03-19	0.68	2020-03-26
2019-12-19	0.51	2019-12-27
2019-09-19	0.27	2019-09-26
2019-06-20	0.37	2019-06-27
2019-03-21	0.35	2019-03-28
2018-12-20	0.41	2018-12-27
2018-09-20	0.22	2018-09-27
2018-06-21	0.44	2018-06-28
2018-03-22	0.22	2018-03-29
2017-12-21	0.95	2017-12-28
2017-09-21	0.33	2017-09-27
2017-06-21	0.35	2017-06-28
2016-12-21	0.46	2016-12-29
2016-09-21	0.38	2016-09-28
2016-06-22	0.31	2016-06-29
2016-03-23	0.37	2016-03-31
2015-12-23	0.21	2015-12-31
2015-09-23	0.13	2015-09-30
2015-06-24	0.68	2015-07-01
2015-03-25	0.44	2015-04-01
2014-12-24	0.41	2015-01-02
2014-09-24	0.24	2014-10-01
2014-06-25	0.39	2014-07-02
2014-03-26	0.22	2014-04-02
2013-12-26	0.17	2014-01-03
2013-09-25	0.23	2013-10-02
2012-12-26	2.23	2013-01-03
2012-09-26	0.23	2012-10-03
2012-06-20	0.26	2012-06-27
2012-03-21	0.15	2012-03-28
2011-12-21	0.18	2011-12-28
2011-09-21	0.20	2011-09-28
2011-06-22	0.28	2011-06-29
2011-03-23	0.61	2011-03-30
2010-12-21	1.12	2010-12-29
2010-09-22	0.18	2010-09-29
2010-06-23	0.21	2010-06-30
2010-03-24	0.43	2010-03-31
2009-12-29	1.03	2010-01-06
2009-09-29	0.08	2009-10-06
2009-06-29	0.57	2009-07-07
2008-12-29	0.49	2009-01-05

公司名称	GRI Bio
行业分类	--
业务描述	GRI Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for inflammatory, fibrotic, and autoimmune diseases. It focuses on its lead program, GRI-0621, an inhibitor of type 1 invariant Natural Killer T (iNKT) cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis. The company was founded by Vipin Kumar Chaturvedi in May 2009 and is headquartered in La Jolla, CA.

GRI Bio GRI 深 沪

2.86

个股概要

财务分析

公司资料

相关新闻

分红派息

相关新闻

公司简介

GRI Bio GRI 深沪